Table 1.
Antimicrobial utilization per antimicrobial class and per infection probability
| DOT (%) | DOT/1000 patient days | DOT (% of total DOT/antibiotic class) | ||||
|---|---|---|---|---|---|---|
| Infection present | Prophylactic treatment | |||||
| High probability | Moderate probability | Low probability | ||||
| Antibacterial class | ||||||
| Aminoglycosides | 474 (1.0) | 10.0 | 388 (81.8) | 67 (14.1) | 5 (1.1) | 6 (1.3) |
| Ansamycins (rifampicin) | 268 (0.5) | 5.7 | 230 (85.8) | 9 (3.4) | 13 (4.9) | 15 (5.6) |
| Carbapenems | 4488 (9.1) | 94.7 | 3438 (76.6) | 697 (15.5) | 221 (4.9) | 110 (2.5) |
| 1st gen. cephalosporins | 2939 (6.0) | 62.0 | – | – | – | 2939 (100) |
| 2nd gen. cephalosporins | 1192 (2.4) | 25.1 | 398 (33.4) | 324 (27.2) | 169 (14.2) | 301 (25.3) |
| 3rd gen. cephalosporins | 1955 (4.0) | 41.2 | 1343 (68.7) | 400 (20.5) | 143 (7.3) | 63 (3.2) |
| Fluoroquinolones | 5385 (11) | 113.6 | 3268 (60.7) | 1285 (23.9) | 367 (6.8) | 448 (8.3) |
| Folate pathway inhibitor | 3105 (6.3) | 65.5 | 896 (28.9) | 319 (10.3) | 142 (4.6) | 1747 (56.3) |
| Glycopeptides | 2966 (6.0) | 62.6 | 2163 (72.9) | 438 (14.8) | 172 (5.8) | 169 (5.7) |
| Glycylcyclines | 319 (0.6) | 6.7 | 242 (75.9) | 63 (19.7) | 11 (3.4) | 2 (0.6) |
| Lincosamides | 806 (1.6) | 17.0 | 564 (70.0) | 140 (17.4) | 42 (5.2) | 60 (7.4) |
| Macrolides | 1421 (2.9) | 30.0 | 834 (58.7) | 215 (15.1) | 84 (5.9) | 284 (20.0) |
| Monobactams | 150 (0.3) | 3.2 | 33 (22.0) | 28 (18.7) | 10 (6.7) | 79 (52.7) |
| Nitrofurans | 59 (0.1) | 1.2 | 19 (32.2) | 16 (27.1) | 7 (11.9) | 17 (28.8) |
| Nitroimidazoles | 1289 (2.6) | 27.2 | 976 (75.7) | 147 (11.4) | 61 (4.7) | 92 (7.1) |
| Oxazolidinones | 1780 (3.6) | 37.6 | 1434 (80.6) | 212 (11.9) | 53 (3.0) | 69 (3.9) |
| Penicillins | 1504 (3.1) | 31.7 | 1212 (80.6) | 188 (12.5) | 86 (5.7) | 15 (1.0) |
| Non-anti-pseudomonal penicillins + beta-lactamase inhibitor | 8136 (16.5) | 171.6 | 3267 (40.2) | 1605 (19.7) | 660 (8.1) | 2588 (31.8) |
| Anti-pseudomonal penicillins + beta-lactamase inhibitor | 10,342 (21.0) | 218.2 | 6405 (61.9) | 2292 (22.2) | 808 (7.8) | 800 (7.7) |
| Phosphonic acids | 27 (0.1) | 0.6 | 3 (11.1) | 17 (63.0) | 6 (22.2) | 1 (3.7) |
| Polymyxins | 469 (1.0) | 9.9 | 311 (66.3) | 97 (20.7) | 19 (4.1) | 42 (9.0) |
| Tetracyclines | 95 (0.2) | 2.0 | 82 (86.3) | 1 (1.1) | 1 (1.1) | 11 (11.6) |
| Total antibacterial | 49,169 (100) | 1037.3 | 27,506 (55.9) | 8560 (17.4) | 3080 (6.3) | 9858 (20.0) |
| Antifungal class | ||||||
| Azoles | 7684 (83.1) | 162.1 | 2123 (27.6) | 415 (5.4) | 222 (2.9) | 4809 (62.6) |
| Echinocandins | 1354 (14.6) | 28.6 | 1022 (75.5) | 176 (13.0) | 93 (6.9) | 56 (4.1) |
| Polyenes | 206 (2.2) | 4.3 | 138 (67.0) | 37 (18.0) | 29 (14.1) | – |
| Total antifungal | 9244 (100) | 195.0 | 3283 (35.5) | 628 (6.8) | 344 (3.7) | 4865 (52.6) |
| Total | 58,413 (100) | 1232.3 | 30,789 (52.7) | 9188 (15.7) | 3424 (5.9) | 14,723 (25.2) |
DOT days of therapy, gen. generation